JP5633025B2 - Ｈｉｇ２およびｕｒｌｃ１０エピトープペプチドならびにそれを含むワクチン - Google Patents

Ｈｉｇ２およびｕｒｌｃ１０エピトープペプチドならびにそれを含むワクチン Download PDF

Info

Publication number
JP5633025B2
JP5633025B2 JP2011507735A JP2011507735A JP5633025B2 JP 5633025 B2 JP5633025 B2 JP 5633025B2 JP 2011507735 A JP2011507735 A JP 2011507735A JP 2011507735 A JP2011507735 A JP 2011507735A JP 5633025 B2 JP5633025 B2 JP 5633025B2
Authority
JP
Japan
Prior art keywords
peptide
hla
cancer
antigen
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011507735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500184A (ja
JP2012500184A5 (enExample
Inventor
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012500184A publication Critical patent/JP2012500184A/ja
Publication of JP2012500184A5 publication Critical patent/JP2012500184A5/ja
Application granted granted Critical
Publication of JP5633025B2 publication Critical patent/JP5633025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011507735A 2008-08-19 2009-08-14 Ｈｉｇ２およびｕｒｌｃ１０エピトープペプチドならびにそれを含むワクチン Active JP5633025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8997208P 2008-08-19 2008-08-19
US61/089,972 2008-08-19
PCT/JP2009/003897 WO2010021112A1 (en) 2008-08-19 2009-08-14 Hig2 and urlc10 epitope peptide and vaccines containing the same

Publications (3)

Publication Number Publication Date
JP2012500184A JP2012500184A (ja) 2012-01-05
JP2012500184A5 JP2012500184A5 (enExample) 2012-09-27
JP5633025B2 true JP5633025B2 (ja) 2014-12-03

Family

ID=41707003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507735A Active JP5633025B2 (ja) 2008-08-19 2009-08-14 Ｈｉｇ２およびｕｒｌｃ１０エピトープペプチドならびにそれを含むワクチン

Country Status (16)

Country Link
US (1) US9119800B2 (enExample)
EP (1) EP2328600B9 (enExample)
JP (1) JP5633025B2 (enExample)
KR (1) KR101713581B1 (enExample)
CN (2) CN102186491B (enExample)
AU (1) AU2009283763B2 (enExample)
BR (1) BRPI0917391A2 (enExample)
CA (1) CA2734467C (enExample)
DK (1) DK2328600T3 (enExample)
ES (1) ES2566011T3 (enExample)
IL (1) IL211117A (enExample)
MX (2) MX355054B (enExample)
RU (1) RU2529373C2 (enExample)
SG (2) SG10201610206VA (enExample)
TW (2) TWI543767B (enExample)
WO (1) WO2010021112A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
EP2872531A4 (en) 2012-07-10 2016-04-06 Oncotherapy Science Inc LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
US10576097B2 (en) * 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
EP3335725B1 (en) 2015-08-10 2024-02-28 Toray Industries, Inc. Pds5a epitopes as immunity inducers
US10676508B2 (en) 2015-08-12 2020-06-09 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
CN110997902B (zh) 2017-06-20 2021-11-30 居里研究所 Suv39h1缺陷的免疫细胞
CN115300609B (zh) * 2021-05-08 2026-07-28 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用
CN120842356B (zh) * 2025-07-25 2026-07-17 广西医科大学附属肿瘤医院 Ly6k抗原表位肽、组合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
ES2340357T3 (es) * 1999-08-05 2010-06-02 Green Peptide Co., Ltd. Antigeno tumoral.
AU7748200A (en) 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
EP1474528A4 (en) 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
US20080286313A1 (en) 2004-06-21 2008-11-20 Kyogo Itoh Peptide Vaccines for the Treatment of Cancers
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
WO2006093337A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
JP5116150B2 (ja) 2005-09-07 2013-01-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP4840858B2 (ja) * 2006-03-16 2011-12-21 学校法人慶應義塾 癌ワクチン
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2185732A1 (en) 2007-07-30 2010-05-19 Oncotherapy Science, Inc. Cancer associated gene ly6k
TW201000115A (en) 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
RU2529373C2 (ru) 2014-09-27
MX337756B (es) 2016-03-17
JP2012500184A (ja) 2012-01-05
US20110243973A1 (en) 2011-10-06
WO2010021112A1 (en) 2010-02-25
KR101713581B1 (ko) 2017-03-08
MX355054B (es) 2018-04-03
CN104958753B (zh) 2018-09-25
CA2734467A1 (en) 2010-02-25
IL211117A0 (en) 2011-04-28
BRPI0917391A2 (pt) 2015-12-01
MX2011001883A (es) 2011-03-29
TW201019952A (en) 2010-06-01
TW201500055A (zh) 2015-01-01
US9119800B2 (en) 2015-09-01
TWI543767B (zh) 2016-08-01
DK2328600T3 (en) 2016-03-29
EP2328600A1 (en) 2011-06-08
ES2566011T3 (es) 2016-04-08
TWI580431B (zh) 2017-05-01
SG193806A1 (en) 2013-10-30
AU2009283763A2 (en) 2011-07-07
KR20110045052A (ko) 2011-05-03
EP2328600B9 (en) 2016-07-13
AU2009283763A1 (en) 2010-02-25
HK1157204A1 (zh) 2012-06-29
EP2328600A4 (en) 2013-03-06
SG10201610206VA (en) 2017-01-27
CN104958753A (zh) 2015-10-07
RU2011110376A (ru) 2012-09-27
CN102186491A (zh) 2011-09-14
CA2734467C (en) 2017-10-03
EP2328600B1 (en) 2016-01-27
IL211117A (en) 2017-03-30
AU2009283763B2 (en) 2014-06-19
CN102186491B (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
JP5640262B2 (ja) Ｃｄｃａ１エピトープペプチドおよびそれを含むワクチン
JP5320544B2 (ja) Ｔｅｍ８ペプチドおよびそれを含むワクチン
JP2012500001A (ja) Ｉｎｈｂｂエピトープペプチドおよびそれを含むワクチン
US9119800B2 (en) HIG2 and URLC10 epitope peptide and vaccines containing the same
US9675680B2 (en) MELK epitope peptides and vaccines containing the same
JP2011523937A (ja) Ｉｑｇａｐ３エピトープペプチドおよびそれを含むワクチン
JP2011522777A (ja) Ｍｙｂｌ２エピトープペプチドおよびそれを含むワクチン
JP5663790B2 (ja) Ｒａｂ６ｋｉｆｌ／ｋｉｆ２０ａエピトープペプチドおよびそれを含むワクチン
HK1157204B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140917

R150 Certificate of patent or registration of utility model

Ref document number: 5633025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250